Triglyceride-rich lipoproteins in non-insulin-dependent diabetes mellitus: Post-prandial metabolism and relation to premature atherosclerosis

European Journal of Clinical Investigation

Volumn 26, Issue 2, 1996, Pages 89-108

  De Man, F H A F ^a   Castro Cabezas, M ^a   Van Barlingen, H H J J ^a   Erkelens, D W ^a   De Bruin, T W A ^a,b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Atherosclerosis; Diabetes mellitus; Hypolipidaemic agents; Insulin resistance; Lipoprotein lipase; Lipoproteins

Indexed keywords

ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; LIPOPROTEIN; TRIACYLGLYCEROL;

ATHEROSCLEROSIS; GOOD CLINICAL PRACTICE; HUMAN; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTPRANDIAL STATE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT;

EID: 0030062904     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2362.1996.114256.x     Document Type: Review

References (266)

1. Garcia MJ, McNamara PM, Gordon T, Kannel WB. Morbidity and mortality in diabetics in the Framingham population. Sixteen year follow-up study. Diabetes 1974;23: 105-11.
2. Kleinman JC, Donahue RP, Harris MI, Finucane FF, Madans JH, Brock DB. Mortality among diabetics in a national sample. Am J Epidemiol 1988;128:389-401.
3. Stamler J. Epidemiology, established major risk factors, and the prevention of coronary heart disease. In: Parmley WW, Chatterjee K, eds. Cardiology. Philadelphia: JB Lippinicott, 1987:1-41.
4. Rubin RJ, Altman WM, Mendelson DN. Health care expenditures for people with diabetes mellilus. J Clin Endocrinol Metab 1994;78:809A-F.
5. Bagdade JD, Porte DJ, Bierman EL. Diabetic lipaemia. A form of acquired fat-induced lipaemia. N Engl J Med 1967; 276:427-33.
6. Vague P, Juhan Vague I, Aillaud MF et al. Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level, and relative body weight in normal and obese subjects. Metabolism 1986;35:250-3.
7. Reaven GM, Chen YD. Role of insulin in regulation of lipoprotein metabolism in diabetes. Diabetes Metab Rev 1988;4:639-52.
8. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988;37:1595-607.
9. Kaplan NM. The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridaemia, and hypertension. Arch Int Med 1989;149:1514-20.
10. Srinivasan SR, Bao W, Berenson GS. Coexistence of increased levels of adiposity, insulin, and blood pressure in a young adult cohort with elevated very-low-density lipoprotein cholesterol: the Bogalusa Heart Study. Metabolism 1993; 42:170-6.
11. Potter van Loon BJ, Kluft C, Radder JK, Blankenstein MA, Meinders AE. The cardiovascular risk factor plasminogen activator inhibitor type 1 is related to insulin resistance. Metabolism 1993;42:945-9.
12. Gordon DJ, Probstfield JL, Garrison RJ et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989;79:8-15.
13. Haffner SM, Fong D, Hazuda HP, Pugh JA, Patterson JK. Hyperinsulinemia, upper body adiposity, and cardiovascular risk factors in non-diabetics. Metabolism 1988;37:338-45.
14. West KM, Ahuja MM, Bennett PH et al. The role of circulating glucose and triglyceride concentrations and their interactions with other 'risk factors' as determinants of arterial disease in nine diabetic population samples from the WHO multinational study. Diabetes Care 1983;6:361-9.
15. Hamsten A, de Faire U, Walldius G et al. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987;2:3-9.
16. Vague J. The degree of masculine differentiation of obesities: A factor determining predisposition to diabetes, atherosclerosis, gout and uric calculus disease. Am J Clin Nutr 1956;4:20-34.
17. Albrink MJ, Meigs JW. Interrelationships between skinfold thickness, serum lipids and blood sugar in normal men. Am J Clin Nutr 1964;15:255-61.
18. Erkelens DW, de Bruin TWA, Castro Cabezas M. Tulp syndrome. Lancet 1993;342:1536-7.
19. Barrett-Connor E, Grundy SM, Holdbrook MJ. Plasma lipids and diabetes mellitus in an adult community. Am J Epidemiol 1982;115:657-63.
20. Barrett-Connor E, Witztum JL, Holdbrook M. A community study of high density lipoproteins in adult noninsulin-dependent diabetics. Am J Epidemiol 1983;117:186-92.
21. Howard BV, Knowler WC, Vasquez B, Kennedy AL, Pettitt DJ, Bennett PH. Plasma and lipoprotein cholesterol and triglyceride in the Pima Indian population. Comparison of diabetics and nondiabetics. Arteriosclerosis 1984;4:462-71.
22. Cambien F, Jacqueson A, Richard JL, Warnet JM, Ducimetiere P, Claude JR. Is the level of serum triglyceride a significant predictor of coronary death in 'normocholesterolemic' subjects? The Paris Prospective Study. Am J Epidemiol 1986;124:624-32.
23. Assmann G, Schulte H. The Prospective Cardiovascular Munster (PROCAM) study: prevalence of hyperlipidaemia in persons with hypertension and or diabetes mellitus and the relationship to coronary heart disease. Am Heart J 1988;116: 1713-24.
24. Briones ER, Mao SJ, Palumbo PJ, O'Fallon WM, Chenoweth W, Kottke BA. Analysis of plasma lipids and apolipoproteins in insulin-dependent and noninsulin-dependent diabetics. Metabolism 1984;33:4-9.
25. Taskinen MR, Beltz WF, Harper I et al. Effects of NIDDM on very-low-density lipoprotein triglyceride and apolipoprotein B metabolism. Studies before and after sulfonylurea therapy. Diabetes 1986;35:1268-77.
26. Taskinen MR, Nikkila EA, Kuusi T, Harmo K. Lipoprotein lipase activity and serum lipoproteins in untreated type 2 (insulin-independent) diabetes associated with obesity. Diabetologia 1982;22:46-50.
27. Barakat HA, Carpenter JW, McLendon VD et al. Influence of obesity, impaired glucose tolerance and NIDDM on LDL structure and composition. Possible link between hyperinsulinemia and atherosclerosis. Diabetes 1990;39:1527-33.
28. Selby JV, Austin MA, Newman B et al. LDL subclass phenotypes and the insulin resistance syndrome in women. Circulation 1993;88:381-7.
29. Richards EG, Grundy SM, Cooper K. Influence of plasma triglycerides on lipoprotein patterns in normal subjects and in patients with coronary artery disease. Am J Cardiol 1989;26: 566-74.
30. Austin MA, King MC, Vranizan KM, Krauss RM. Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary artery disease. Circulation 1990;82:495-506.
31. DeFronzo RA, Ferrani E. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidaemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991;14:173-94.
32. Austin M, Breslow JL, Hennekens CH, Buring JE, Willet WC, Krauss RM. Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA 1988;260:1917-21.
33. Crouse JR, Parks JS, Schey HM, Kahl RF. Studies of low density lipoprotein molecular weight in human beings with coronary artery disease. J Lipid Res 1985;26:566-74.
34. Campos H, Genest JJ, Blijlevens E et al. Low density lipoprotein particle size and coronary artery disease. Arterioscler Thromb 1992;12:187-95.
35. Santen RJ, Willis PW, Fajans SS. Atherosclerosis in diabetes mellitus. Correlations with serum lipid levels, adiposity, and serum insulin level. Arch Intern Med 1972;130:833-43.
36. Janka HU. Five-year incidence of major macrovascular complications in diabetes mellitus. Horm Metab Res Suppl 1985; 15:15-9.
37. Laakso M, Ronnemaa T, Pyorala K, Kallio V, Puukka P, Penttila I. Atherosclerotic vascular disease and its risk factors in non-insulin-dependent diabetic and nondiabetic subjects in Finland. Diabetes Care 1988;11:449-63.
38. Laakso M, Pyorala K, Sarlund H, Voutilainen E. Lipid and lipoprotein abnormalities associated with coronary heart disease in patients with insulin-dependent diabetes mellitus. Arterosclerosis 1986;6:679-84.
39. Ronnemaa T, Laakso M, Kallio V, Pyorala K, Marniemi J, Puukka P. Serum lipids, lipoproteins, and apolipoproteins and the excessive occurrence of coronary heart disease in non-insulin-dependent diabetic patients. Am J Epidemiol 1989; 130:632-45.
40. Fontbonne A, Eschwege E, Cambien F et al. Hypertriglyceridaemia as a risk factor of coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes. Results from the 11-year follow-up of the Paris Prospective Study. Diabetologia 1989;32:300-4.
41. Kwiterovich PO, Jr., Coresh J, Bachorik PS. Prevalence of hyperapobetalipoproteinaemia and other lipoprotein phenotypes in men (aged ≤ 50 years) and women (≤ 60 years) with coronary artery disease. Am J Cardiol 1993;71: 631-9.
42. Austin MA. Plasma triglyceride and coronary heart disease. Arterioscler Thromb 1991;11:2-14.
43. Criqui MH, Heiss G, Cohn R et al. Plasma triglyceride level and mortality from coronary heart disease. N Engl J Med 1993;328:1220-5.
44. Austin MA. Triglycerides and small, dense LDL as risk factors for coronary heart disease. Proceedings of the 3rd international symposium Multiple Risk factors in Cardiovascular Disease, Florence (Italy); Lorenzini Foundation Symposium 237; Milan, 1994:7.
45. Glomset JA. The plasma lecithin:cholesterol acyltransferase reaction. J Lipid Res 1968;9:155-67.
46. Reichl D, Miller NE. Pathophysiology of reverse cholesterol transport. Insights from inherited disorders of lipoprotein metabolism. Arteriosclerosis 1989;9:785-97.
47. Rhoads GG, Gulbrandsen CL, Kagan A. Serum lipoproteins and coronary heart disease in a population study of Hawaii Japanese men. N Engl J Med 1976;294:293-8.
48. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 1977;62:707-14.
49. Albrink MJ, Krauss RM, Lindgrem FT, von-der-Groeben J, Pan S, Wood PD. Intercorrelations among plasma high density lipoprotein, obesity and triglycerides in a normal population. Lipids 1980;15:668-76.
50. Davis CE, Gordon D, LaRosa J, Wood PD, Halperin M. Correlations of plasma high-density lipoprotein cholesterol levels with other plasma lipid and lipoprotein concentrations. Circulation 1980;62:IV24-30.
51. Castro Cabezas M, de Bruin TWA, Kock LAW, Jansen H, Erkelens DW. Impaired fatty acid metabolism in familial combined hyperlipidaemia: A mechanism associating hepatic apolipoprotein B overproduction and insulin resistance. J Clin Invest 1993;9223:160-8.
52. Wilson DE, Lees RS. Metabolic relationships among the plasma lipoproteins. Reciprocal changes in the concentrations of very low and low density lipoproteins in man. J Clin Invest 1972;51:1051-7.
53. Behr SR, Patsch JR, Forte T, Bensadoun A. Plasma lipoprotein changes resulting from immunologically blocked lipolysis. J Lipid Res 1981;22:443-51.
54. Brunzell JD. Familial lipoprotein lipase deficiency and other causes of the chylomicronemia syndrome. In: The metabolic basis of inherited disease. 6th ed. McGraw-Hill, 1989:1165-80.
55. Ito Y, Azrolan N, O'Connell A, Walsh A, Breslow JL. Hypertriglyceridaemia as a result of human apo CIII gene expression in transgenic mice. Science 1990;249:790-3.
56. Scott J, Navaratnam N, Bhattacharya S, Morrison JR. The apolipoprotein B messenger RNA editing enzyme. Curr Opin Lipidol 1994;5:87-93.
57. Dixon JL, Furukawa S, Ginsberg HN. Oleate stimulates the secretion of apolipoprotein B-containing lipoproteins from HepG2 cells by inhibiting early intracellular degradation of apolipoprotein B. J Biol Chem 1991;266:5080-6.
58. Sparks JD, Sparks CE. Hormonal regulation of lipoprotein assembly and secretion. Curr Opin Lipidol 1993;4:177-86.
59. Wetterau JR, Aggerbeck LP, Bouma M-E et al. Absence of microsomal triglyceride transfer protein in individuals with abetalipoproteinaemia. Science 1992;258:999-1001.
60. Erkelens DW, Chen C, Mitchell CD, Glomset JA. Studies of the interaction between apolipoproteins A and C and triacylglycerol-rich particles. Biochim Biophys Acta 1981;665:221-33.
61. Mahley RW, Hussain MM. Chylomicron and chylomicron remnant metabolism. Curr Opin Lipidol 1991;2:170-6.
62. Saxena U, Witte LD, Goldberg IJ. Release of endothelial cell lipoprotein lipase by plasma lipoproteins and free fatty acids. J Biol Chem 1989;264:4349-55.
63. Peterson J, Bihain BE, Bengtsson Olivecrona G, Deckelbaum RJ, Carpentier YA, Olivecrona T. Fatty acid control of lipoprotein lipase: a link between energy metabolism and lipid transport. Proc Natl Acad Sci USA 1990;87:909-13.
64. Redgrave TG, Calson LA. Changes in plasma very low density and low density lipoprotein content, composition and size after a fatty meal in normo-and hypertriglyceridaemic man. J Lipid Res 1979;20:217-29.
65. Berr F. Characterization of chylomicron remnant clearance by retinyl palmitate label in normal humans. J Lipid Res 1992;33:915-30.
66. Castro Cabezas M, de Bruin TWA, Kock LA et al. Simvastatin improves chylomicron remnant removal in familial combined hyperlipidaemia without changing chylomicron conversion. Metabolism 1993;42:497-503.
67. Choi SY, Fong LG, Kirven MJ, Cooper AD. Use of an anti-low density lipoprotein receptor antibody to quantify the role of the LDL receptor in the removal of chylomicron remnants in the mouse in vivo. J Clin Invest 1991;88:1173-81.
68. Szanto A, Balasubramaniam S, Roach PD, Nestel PJ. Modulation of the low-density-lipoprotein-receptor-related protein and its relevance to chylomicron-remnant metabolism. Biochem J 1992;288:791-4.
69. Kita T, Goldstein JL, Brown MS, Watanabe Y, Hornick CA, Havel RJ. Hepatic uptake of chylomicron remnants in WHHL rabbits: a mechanism genetically distinct from the low density lipoprotein receptor. Proc Natl Acad Sci USA 1982;79:3623-7.
70. Hoeg JM, Demosky SJJ, Gregg RE, Schaefer EJ, Brewer HBJ. Distinct hepatic receptors for low density lipoprotein and apolipoprotein E in humans. Science 1985;227:759-61.
71. Rubinsztein DC, Cohen JC, Berger GM, Van der Westhuyzen DR, Coetzee GA, Gevers W. Chylomicron remnant clearance from the plasma is normal in familial hypercholesterolemic homozygotes with defined receptor defects. J Clin Invest 1990;86:1306-12.
72. Herz J, Hamann U, Rogne S, Myklebost O, Gausepohl H, Stanley KK. Surface location and high affinity for calcium of a 500-kd liver membrane protein closely related to the LDL-receptor suggest a physiological role as lipoprotein receptor. EMBO J 1988;7:4119-27.
73. Kowal RC, Herz J, Weisgraber KH, Mahley RW, Brown MS, Goldstein JL. Opposing effects of apolipoproteins E and C on lipoprotein binding to low density lipoprotein receptor-related protein. J Biol Chem 1990;265:10771-9.
74. Beisiegel U, Weber W, Ihrke G, Herz J, Stanley KK. The LDL-receptor-related protein, LRP, is an apolipoprotein E-binding protein. Nature 1989;341:162-4.
75. Kowal RC, Herz J, Goldstein JL, Esser V, Brown MS. Low density lipoprotein receptor-related protein mediates uptake of cholesteryl esters derived from apoprotein E-enriched lipoproteins. Proc Natl Acad Sci USA 1989;86:5810-4.
76. Beisiegel U, Weber W, Bengtsson Olivecrona G. Lipoprotein lipase enhances the binding of chylomicrons to low density lipoprotein receptor-related protein. Proc Natl Acad Sci USA 1991;88:8342-6.
77. Willnow TE, Sheng Z, Ishibashi S, Herz J. Inhibition of hepatic chylomicron remnant uptake by gene transfer of a receptor antagonist. Science 1994;264:1471-4.
78. 77a Willnow TE, Armstrong SA, Hammer RE, Herz J. Functional expression of low density lipoprotein receptor-related protein is controlled by receptor-associated protein in vivo. Proc Natl Acad Sci USA 1995;92:4537-41.
79. Eckel RH. Lipoprotein lipase. A multifunctional enzyme relevant to common metabolic diseases N Engl J Med 1989; 320:1060-8.
80. Ji ZS, Brecht WJ, Miranda RD, Hussain MM, Innerarity TL, Mahley RW. Role of heparan sulphate proteoglycans in the binding and uptake of apolipoprotein E-enriched remnant lipoproteins by cultured cells. J Biol Chem 1993;268:10160-7.
81. Mulder M, Lombardi P, Jansen H, van Berkel TJ, Frants RR, Havekes LM. Low density lipoprotein receptor internalizes low density and very low density lipoproteins that are bound to heparan sulphate proteoglycans via lipoprotein lipase. J Biol Chem 1993;268:9369-75.
82. Connelly PW, Maguire GF, Lee M, Little JA. Plasma lipoproteins in familial hepatic lipase deficiency. Arteriosclerosis 1990;10:40-8.
83. Sultan F, Lagrange D, Jansen H, Griglio S. Inhibition of hepatic lipase activity impairs chylomicron remnant removal in rats. Biochim Biophys Acta 1990;1042:150-2.
84. Demacker PN, Staels B, Stalenhoef AF, Auwerx J. Increased removal of beta-very low density lipoproteins after ethinyl estradiol is associated with increased mRNA levels for hepatic lipase, lipoprotein lipase, and the low density lipoprotein receptor in Watanabe heritable hyperlipidaemic rabbits. Arterioscler Thromb 1991;11:1652-9.
85. Sparks JD, Sparks CE, Miller LL. Insulin effects on apolipoprotein B production by normal, diabetic and treated diabetic rat liver and cultured hepatocytes. Biochem J 1989;261:83-8.
86. Lewis GF, Uffelman KD, Szeto LW, Steiner G. Effects of acute hyperinsulinemia on VLDL triglyceride and VLDL apo B production in normal weight and obese individuals. Diabetes 1993;42:833-42.
87. Lewis GF, Uffelman KD, Szeto LW, Weller B, Steiner G. Interaction between fatty acids and insulin in the acute control of very low density lipoprotein production in humans. J Clin Invest 1995;95:158-66.
88. Cianflone K, Dhan S, Monge JC, Sniderman AD. Pathogenesis of carbohydrate induced hypertriglyceridaemia using HepG2 cells as a model system. Arteriosclerosis Thromb 1992;12: 271-7.
89. Windler EE, Kovanen PT, Chao YS, Brown MS, Havel RJ, Goldstein JL. The estradiol-stimulated lipoprotein receptor of rat liver. A binding site that mediates the uptake of rat lipoproteins containing apoproteins B and E. J Biol Chem 1980;255:10464-71.
90. Chappell DA, Fry GL, Waknitz MA, Iverius P-H, Williams SE, Strickland DK. The low density lipoprotein receptor-related protein/alpha2-macroglobulin receptor binds and mediates catabolism of bovine milk lipoprotein lipase. J Biol Chem 1992;267:25764-7.
91. Chappell DA, Fry GL, Waknitz MA et al. Lipoprotein lipase induces catabolism of normal triglyceride-rich lipoproteins via the low density lipoprotein receptor/alpha2-macroglobulin receptor in vitro. A process facilitated by cell-surface proteoglycans. J Biol Chem 1993;268:14168-75.
92. Obunike JC, Edwards IJ, Rumsey SC et al. Cellular differences in lipoprotein lipase-mediated uptake of low density lipoproteins. J Biol Chem 1994;269:13129-35.
93. Shimano H, Namba Y, Ohsuga J et al. Secretion-recapture process of apolipoprotein E in hepatic uptake of chylomicron remnants in transgenic mice. J Clin Invest 1994;93:2215-23.
94. Ji Z-S, Fazio S, Lee Y-L, Mahley RW. Secretion-capture role for apolipoprotein E in remnant lipoprotein metabolism involving cell surface heparan sulphate proteoglycans. J Biol Chem 1994;269:2764-72.
95. Zambon A, Bijvoet S, Moorjani S et al. Prevention of raised low-density lipoprotein cholesterol in a patient with familial hypercholesterolemia and lipoprotein lipase deficiency. Lancet 1993;341:1119-21.
96. Redgrave TG, Small DM. Quantitation of the transfer of surface phospholipid of chylomicrons to the high density lipoprotein fraction during the catabolism of chylomicrons in the rat. J Clin Invest 1979;64:162-71.
97. Schaefer EJ, Wetzel MG, Bengtsson G, Scow RO, Brewer HBJ, Olivecrona T. Transfer of human lymph chylomicron constituents to other lipoprotein density fractions during in vitro lipolysis. J Lipid Res 1982;23:1259-73.
98. Patsch JR, Prasad S, Gotto AM, Jr., Patsch W. High density lipoprotein 2. Relationship of the plasma levels of this lipoprotein species to its composition, to the magnitude of postprandial lipaemia, and to the activities of lipoprotein lipase and hepatic lipase. J Clin Invest 1987;80:341-7.
99. Karpe F, Bard JM, Steiner G, Carlson LA, Fruchart JC, Hamsten A. HDLs and alimentary lipaemia. Studies in men with previous myocardial infarction at young age. Arterioscler Thromb 1993;13:11-22.
100. Eisenberg S. High density lipoprotein metabolism. J Lipid Res 1984;25:1017-58.
101. Castro Cabezas M, Van Heusden GP, de Bruin TW et al. Reverse cholesterol transport: relationship between free cholesterol uptake and HDL3 in normolipidaemic and hyperlipidaemic subjects. Eur J Clin Invest 1993;23:122-9.
102. Barter PJ, Hopkins GJ, Calvert GD. Transfers and exchanges of esterified cholesterol between plasma lipoproteins. Biochem J 1982;208:1-7.
103. Dullaart RP, Groener JE, Erkelens DW. Effect of the composition of very low and low density lipoproteins on the rate of cholesterylester transfer from high density lipoproteins in man, studied in vitro. Eur J Clin Invest 1987;17:241-8.
104. Schaefer EJ, Wetzel MG, Bengtsson G, Scow RO, Brewer HB Jr, Olivecrona T. Transfer of human lymph chylomicron constituents to other lipoprotein density fractions during in vitro lipolysis. J Lipid Res 1982;23:1259-73.
105. Rotter IJ, Bu X, Cantor RM et al. Multiple genes determine LDL particle size phenotype in coronary artery disease families. Circulation 1994;88:509.
106. Olefsky JM, Crapo P, Reaven GM. Post-prandial plasma triglyceride and cholesterol responses to a low-fat meal. Am J Clin Nutr 1976;29:535-9.
107. Goodman DS, Huang HS, Shiratori M. Tissue distribution and metabolism of newly absorbed vitamin A in the rat. J Lipid Res 1965;6:390-6.
108. Berr F, Kern FJ. Plasma clearance of chylomicrons labeled with retinyl palmitate in healthy human subjects. J Lipid Res 1984;25:805-12.
109. Nakandakare ER, Lottenberg SA, Oliveira HC et al. Simultaneous measurements of chylomicron lipolysis and remnant removal using a doubly labeled artificial lipid emulsion: studies in normolipidaemic and hyperlipidaemic subjects. J Lipid Res 1994;35:143-52.
110. Hospattankar AV, Fairwell T, Meng M, Ronan R, Brewer HBJ. Identification of sequence homology between human plasma apolipoprotein B-100 and apolipoprotein B-48. J Biol Chem 1986;261:9102-4.
111. Schneeman BO, Kotite L, Todd KM, Havel RJ. Relationships between the responses of triglyceride-rich lipoproteins in blood plasma containing apolipoproteins B-48 and B-100 to a fat-containing meal in normolipidaemic humans. Proc Natl Acad Sci USA 1993;90:2069-73.
112. Karpe F, Hamsten A. Determination of apolipoproteins B-48 and B-100 in triglyceride-rich lipoproteins by analytical SDS-PAGE. J Lipid Res 1994;35:1311-7.
113. Howard BV, Xiaoren P, Harper I, Foley JE, Cheung MC, Taskinen MR. Effect of sulfonylurea therapy on plasma lipids and high-density lipoprotein composition in non-insulin-dependent diabetes mellitus. Am J Med 1985;79:78-85.
114. Ginsberg H, Grundy SM. Very low density lipoprotein metabolism in non-ketotic diabetes mellitus: effect of dietary restriction. Diabetologia 1982;23:421-5.
115. Kissebah AH, Alfarsi S, Evans DJ, Adams PW. Integrated regulation of very low density lipoprotein triglyceride and apolipoprotein-B kinetics in non-insulin-dependent diabetes mellitus. Diabetes 1982;31:217-25.
116. Howard BV, Abbott WG, Beltz WK et al. Integrated study of low density lipoprotein metabolism and very low density lipoprotein metabolism in non-insulin-dependent diabetes. Metabolism 1987;36:870-7.
117. Basso LV, Havel RJ. Hepatic metabolism of free fatty acids in normal and diabetic dogs. J Clin Invest 1970;49:537-47.
118. Reaven GM, Mondon CE. Effect of in vivo plasma insulin levels on the relationship between perfusate free fatty acid concentration and triglyceride secretion by perfused rat livers. Horm Metab Res 1984;16:230-2.
119. Hoffman BB, Dall Aglio E, Hollenbeck C, Chang H, Reaven GM. Suppression of free fatty acids and triglycerides in normal and hypertriglyceridaemic rats by the adenosine receptor agonist phenylisopropyladenosine. J Pharmacol Exp Ther 1986;239:715-8.
120. Brunzell JD, Porte DJ, Bierman EL. Reversible abnormalities in postheparin lipolytic activity during the late phase of release in diabetes mellitus (postheparin lipolytic activity in diabetes). Metabolism 1975;24:1123-37.
121. Nikkila EA, Huttunen JK, Ehnholm C. Postheparin plasma lipoprotein lipase and hepatic lipase in diabetes mellitus. Relationship to plasma triglyceride metabolism. Diabetes 1977;26:11-21.
122. Pfeifer MA, Brunzell JD, Best JD, Judzewitsch RG, Halter JB, Porte DJ. The response of plasma triglyceride, cholesterol, and lipoprotein lipase to treatment in non-insulin-dependent diabetic subjects without familial hypertriglyceridaemia. Diabetes 1983;32:525-31.
123. Groop LC, Widen E, Franssila-Kallunki A et al. Different effects of insulin and oral antidiabetic agents on glucose and energy metabolism in type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1989;32:599-605.
124. Kashyap ML, Barnhart RL, Srivastava LS et al. Alimentary lipaemia: plasma high-density lipoproteins and apolipoproteins CII and CIII in healthy subjects. Am J Clin Nutr 1983; 37:233-43.
125. Cortner JA, Coates PM, Le NA et al. Kinetics of chylomicron remnant clearance in normal and in hyperlipoproteinemic subjects. J Lipid Res 1987;28:195-206.
126. Lewis GF, O'Meara NM, Soltys PA et al. Fasting hypertriglyceridaemia in noninsulin-dependent diabetes mellitus is an important predictor of post-prandial lipid and lipoprotein abnormalities. J Clin Endocrinol Metab 1991;72:934-44.
127. Chen YD, Swami S, Skowronski R, Coulston A, Reaven GM. Differences in post-prandial lipaemia between patients with normal glucose tolerance and noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1993;76:172-7.
128. Syvänne M, Hilden H, Taskinen M-R. Abnormal metabolism of post-prandial lipoproteins in patients with non-insulin dependent diabetes mellitus is not related to coronary artery disease. J Lipid Res 1994;35:15-26.
129. Chen YD, Swami S, Skowronski R, Coulston A, Reaven GM. Effect of variations in dietary fat and carbohydrate intake on post-prandial lipaemia in patients with noninsulin dependent diabetes mellitus. J Clin Endocrinol Metab 1993;76:347-51.
130. O'Brien T, Nguyen TT, Buithieu J, Kottke BA. Lipoprotein compositional changes in the fasting state and post-prandial state on a high-carbohydrate low-fat and a high-fat diet in subjects with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1993;77:1345-51.
131. Lewis GF, O'Meara NM, Soltys PA et al. Post-prandial lipoprotein metabolism in normal and obese subjects: comparison after the vitamin A fat-loading test. J Clin Endocrinol Metab 1990;71:1041-50.
132. Zilversmit DB. Atherogenesis: a post-prandial phenomenon. Circulation 1979;60:473-85.
133. Patsch JR, Miesenböck G, Hopferwieser T et al. Relation of triglyceride metabolism and coronary artery disease. Studies in the post-prandial state. Arterioscler Thromb 1992;12:1336-45.
134. Groot PH, van Stiphout WA, Krauss XH et al. Post-prandial lipoprotein metabolism in normolipidaemic men with and without coronary artery disease. Arterioscler Thromb 1991; 11:653-62.
135. Havel RJ. Familial dysbetalipoproteinaemia. New aspects of pathogenesis and diagnosis. Med Clin North Am 1982;66: 441-54.
136. Kane JP, Chen GC, Hamilton RL, Hardman DA, Malloy MJ, Havel RJ. Remnants of lipoproteins of intestinal and hepatic origin in familial dysbetalipoproteinaemia. Arteriosclerosis 1983;3:47-56.
137. Thompson KH, Zilversmit DB. Plasma very low density lipoprotein (VLDL) in cholesterol-fed rabbits: chylomicron remnants or liver lipoproteins?. J Nutr 1983;113:2002-10.
138. Floren CH, Albers JJ, Bierman EL. Uptake of chylomicron remnants causes cholesterol accumulation in cultured human arterial smooth muscle cells. Biochim Biophys Acta 1981;663: 336-49.
139. Simons LA, Dwyer T, Simons J et al. Chylomicrons and chylomicron remnants in coronary artery disease: a case-control study. Atherosclerosis 1987;65:181-9.
140. Weintraub M, Burstein A, Rassin T et al. Severe defect in clearing post-prandial chylomicron remnants in dialysis patients. Kidney Int 1992;42:1247-52.
141. Chung BH, Segrest JP. Cytotoxicity of remnants of triglyceride-rich lipoproteins: an atherogenic insult?. Adv Exp Med Biol 1991;285:341-51.
142. Syvänne M, Ahola M, Lahdenperä S et al. High density lipoprotein subfractions in non-insulin-dependent diabetes mellitus and coronary artery disease. J Lipid Res 1995;36: 573-82.
143. Cohn JS, McNamara JR, Cohn SD, Ordovas JM, Schaefer EJ. Plasma apolipoprotein changes in the triglyceride-rich lipoprotein fraction of human subjects fed a fat-rich meal. J Lipid Res 1988;29:925-36.
144. Marsh JB, Sparks CE. The effect of fasting on the secretion of lipoproteins and two forms of apo B by perfused rat liver. Proc Soc Exp Biol Med 1982;170:178-81.
145. Ellsworth JL, Erickson SK, Cooper AD. Very low and low density lipoprotein synthesis and secretion by the human hepatoma cell line Hep-G2: effects of free fatty acid. J Lipid Res 1986;27:858-74.
146. Wilcox HG, Heimberg M. Secretion and uptake of nascent hepatic very low density lipoprotein by perfused livers from fed and fasted rats. J Lipid Res 1987;28:351-60.
147. Brunzell JD, Hazzard WR, Porte DJ, Bierman EL. Evidence for a common, saturable, triglyceride removal mechanism for chylomicrons and very low density lipoproteins in man. J Clin Invest 1973;52:1578-85.
148. Robins SJ, Fasulo JM, Robins VF, Patton GM. Response of serum triglycerides of endogenous origin to the administration of triglyceride-rich lipid particles. Am J Physiol 1989;257: E860-5.
149. Potts JL, Fisher RM, Humphreys SM, Coppack SW, Gibbons GF, Frayn KN. Peripheral triacylglycerol extraction in the fasting and post-prandial states. Clin Sci 1991;81:621-6.
150. Yki-Jarvinen H, Taskinen MR, Koivisto VA, Nikkila EA. Response of adipose tissue lipoprotein lipase activity and serum lipoproteins to acute hyperinsulinaemia in man. Diabetologia 1984;27:364-9.
151. Sadur CN, Yost TJ, Eckel RH. Insulin responsiveness of adipose tissue lipoprotein lipase is delayed but preserved in obesity. J Clin Endocrinol Metab 1984;59:1176-82.
152. Bengtsson G, Olivecrona T. Apolipoprotein CII enhances hydrolysis of monoglycerides by lipoprotein lipase, but the effect is abolished by fatty acids. FEBS Lett 1979;106:345-8.
153. Bengtsson G, Olivecrona T. Lipoprotein lipase. Mechanism of product inhibition. Eur J Biochem 1980;106:557-62.
154. Posner I, DeSanctis J. Kinetics of product inhibition and mechanisms of lipoprotein lipase activation by apolipoprotein C-II. Biochemistry 1987;26:3711-7.
155. Taskinen MR, Bogardus C, Kennedy A, Howard BV. Multiple disturbances of free fatty acid metabolism in noninsulin-dependent diabetes. Effect of oral hypoglycaemic therapy. J Clin Invest 1985;76:637-44.
156. Groop LC, Bonadonna RC, DelPrato S et al. Glucose and free fatty acid metabolism in non-insulin-dependent diabetes mellitus. Evidence for multiple sites of insulin resistance. J Clin Invest 1989;84:205-13.
157. Groop LC, Saloranta C, Shank M, Bonadonna RC, Ferrannini E, DeFronzo RA. The role of free fatty acid metabolism in the pathogenesis of insulin resistance in obesity and non-insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1991;72:96-107.
158. Fraze E, Donner CC, Swislocki AL, Chiou YA, Chen YD, Reaven GM. Ambient plasma free fatty acid concentrations in noninsulin-dependent diabetes mellitus: evidence for insulin resistance. J Clin Endocrinol Metab 1985;61:807-11.
159. Swislocki AL, Chen YD, Golay A, Chang MO, Reaven GM. Insulin suppression of plasma-free fatty acid concentration in normal individuals and patients with type 2 (non-insulin-dependent) diabetes. Diabetologia 1987;30:622-6.
160. Randle PJ, Garland PB, Hales CN, Newsholme EA. The glucose fatty acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1963;785-9.
161. DeFronzo RA, Gunnarson R, Bjorkman O, Olsson M, Wahren J. Effects of insulin on peripheral and splanchnic glucose metabolism in non-insulin dependent diabetes mellitus. J Clin Invest 1985;76:149-55.
162. McGarry JD. What if Minkowski had been ageusic? An alternative angle on diabetes. Science 1992;258:766-70.
163. Clark AB, Quarfordt SH. Apolipoprotein effects on the lipolysis of perfused triglyceride by heparin-immobilized milk lipase. J Biol Chem 1985;260:4778-83.
164. 2-macroglobulin in adipocytes. J Biol Chem 1993;268: 974-81.
165. 163a Hussain MM, Mahley RW, Boyles JK, Lindquist PA, Brecht WJ, Innerarity TL. Chylomicron metabolism. Chylomicron uptake by bone marrow in different animal species. J Biol Chem 1989;264:17931-8.
166. Bagdade JD, Lane JT, Subbaiah PV, Otto ME, Ritter MC. Accelerated
167. Tall A, Sammett D, Granot E. Mechanisms of enhanced cholesteryl ester transfer from high density lipoproteins to apolipoprotein B-containing lipoproteins during alimentary lipaemia. J Clin Invest 1986;77:1163-72.
168. Marotti KR, Castle CK, Boyle TP, Lin AH, Murray RW, Melchior GW. Severe atherosclerosis in transgenic mice expressing simian cholesteryl ester transfer protein. Nature 1993;364:73-5.
169. Curtiss LK, Witzum JL. Plasma apolipoproteins AI, AII, B, CI, and E are glycosylated in hyperglycaemic diabetics. Diabetes 1984;33:5A.
170. Kortlandt W, van Rijn HJM, Erkelens DW. Glycation and lipoproteins. Diab Nutr Metab 1993;6:321-9.
171. Weisgraber KH, Innerarity TL, Mahley RW. Role of the lysine residues of plasma lipoproteins in high affinity binding to cell surface receptors in human fibroblasts. J Biol Chem 1978;253:9053-62.
172. Steinbrecher UP, Witztum JL. Glycosylation of low-density lipoproteins to an extent comparable to that seen in diabetes slows their catabolism. Diabetes 1984;33:130-4.
173. Yamamoto M, Ranganathan S, Kottke BA. Metabolism of glycosylated very-low-density lipoproteins in human skin fibroblasts. Biochim Biophys Acta 1986;875:410-3.
174. Mamo JCL, Szeto L, Steiner G. Glycation of very low density lipoproteins from rat plasma impairs its catabolism. Diabetologia 1990;33:339-45.
175. Clinical practice Recommendations, American Diabetes Association 1991-1992. Role of cardiovascular risk factors in prevention and treatment of macrovascular disease in diabetes. Diabetes Care 1992;15(suppl 2):68-74.
176. Baynes JW. Role of oxidative stress in development of complications in diabetes. Diabetes 1991;40:405-12.
177. Weisweiler P, Drosner N, Schwandt P. Dietary effects on very-low-density lipoproteins in type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1982;23:101-3.
178. Kennedy L, Walshe K, Hadden DR, Weaver JA, Buchanan KD. The effect of intensive dietary therapy on serum high density lipoprotein cholesterol in patients with Type 2 (non-insulin-dependent) diabetes mellitus: a prospective study. Diabetologia 1982;23:24-7.
179. Taylor KG, John WG, Matthews KA, Wright AD. A prospective study of the effect of 12 months treatment on serum lipids and apolipoproteins A-I and B in Type 2 (non-insulin-dependent) diabetes. Diabelologia 1982;23:507-10.
180. Wales JK. Treatment of type 2 (non-insulin-dependent) diabetic patients with diet alone. Diabetologia 1982;23:240-5.
181. Rabkin SW, Boyko E, Wilson A, Streja DA. A randomized clinical trial comparing behavior modification and individual counseling in the nutritional therapy of non-insulin-dependent diabetes mellilus: comparison of the effect on blood sugar, body weight, and serum lipids. Diabetes Care 1983;6: 50-6.
182. Liu GC, Coulston AM, Lardinois CK, Hollenbeck CB, Moore JG, Reaven GM. Moderate weight loss and sulfonylurea treatment of non-insulin-dependent diabetes mellitus. Combined effects. Arch Intern Med 1985;145:665-9.
183. American Diabetes Association. Diabetes mellilus and exercise: position statement. Diabeles Care 1990;13:804-5.
184. American Diabetes Association. Exercise and NIDDM: technical review. Diabetes Care 1990;13:785-9.
185. Ronnemaa T, Marniemi J, Puukka P, Kuusi T. Effects of long-term physical exercise on lipid levels, lipoproteins and lipid metabolizing enzymes in type 2 (non-insulin-dependent) diabetic patients. Diabetes Res 1988;7:79-84.
186. Howard BV, Savage PJ, Nagulesparan M, Bennion LJ, Davis M, Bennett PH. Changes in plasma lipoproteins accompanying diet therapy in obese diabetics. Atherosclerosis 1979;33: 445-56.
187. Hughes TA, Gwynne JT, Switzer BR, Herbst C, White G. Effects of caloric restriction and weight loss on glycaemic control, insulin release and resistance, and atherosclerotic risk in obese patients with type II diabetes mellitus. Am J Med 1984;77:7-17.
188. Reaven GM. Abnormal lipoprotein metabolism in non-insulin-dependent diabetes mellitus. Pathogenesis and treatment. Am J Med 1987;83:31-40.
189. Winocour PH, Laker MF. Drug therapy for diabetic dyslipoproteinaemia: A practical approach. Diabetic Medicine 1990; 7:292-8.
190. Stern MP, Haffner SM. Dyslipidaemia in type II diabetes. Implications for therapeutic intervention. Diabetes Care 1991;14:1144-59.
191. American Diabetes Association. Nutritional recommendations and principles for individuals with diabetes mellitus. Diabetes Care 1979;2:520-3.
192. Weinsier RL, Seeman A, Herrera MG, Assal JP, Soeldner JS, Gleason RE. High- and low-carbohydrate diets in diabetes mellitus. Study of effects on diabetic control, insulin secretion, and blood lipids. Ann Intern Med 1974;80:332-41.
193. Anderson JW, Ward K. Long-term effects of high-carbohydrate, high-fiber diets on glucose and lipid metabolism: a preliminary report on patients with diabetes. Diabetes Care 1978;1:77-82.
194. Simpson RW, Mann JI, Eaton J, Moore RA, Carter R, Hockaday TD. Improved glucose control in maturity-onset diabetes treated with high-carbohydrate-modified fat diet. Br Med J 1979;1:1753-6.
195. American Diabetes Association. Nutritional recommendations and principles for individuals with diabetes mellitus: 1986. Diabetes Care 1987;10:126-32.
196. Coulston AM, Hollenbeck CB, Swislocki AL, Chen YD, Reaven GM. Deleterious metabolic effects of high-carbohydrate, sucrose-containing diets in patients with non-insulin-dependent diabetes mellitus. Am J Med 1987;82: 213-20.
197. Coulston AM, Hollenbeck CB, Swislocki AL, Reaven GM. Persistence of hypertriglyceridaemic effect of low-fat high-carbohydrate diets in NIDDM patients. Diabetes Care 1989; 12:94-101.
198. Cohen JC, Schall R. Reassessing the effects of simple carbohydrates on the serum triglyceride responses to fat meals. Am J Clin Nutr 1988;48:1031-4.
199. Riccardi G, Rivellese AA. Effects of dietary fiber and carbohydrate on glucose and lipoprotein metabolism in diabetic patients. Diabetes Care 1991;14:1115-25.
200. Herold PM, Kinsella JE. Fish oil consumption and decreased risk of cardiovascular disease: a comparison of findings from animal and human feeding trials. Am J Clin Nutr 1986;43: 566-98.
201. Sanders TA, Roshanai E. The influence of different types of omega 3 polyunsaturated fatty acids on blood lipids and platelet function in healthy volunteers. Clin Sci 1983;64:91-9.
202. Glauber H, Wallace P, Griver K, Brechtel G. Adverse metabolic effect of omega-3 fatty acids in non-insulin-dependent diabetes mellitus. Ann Intern Med 1988;108:663-8.
203. Friday KE, Childs MT, Tsunehara CH, Fujimoto WY, Bierman EL, Ensinck JW. Elevated plasma glucose and lowered triglyceride levels from omega-3 fatty acid supplementation in type II diabetes. Diabetes Care 1989;12:276-81.
204. Vessby B, Karlstrom B, Boberg M, Lithell H, Berne C. Polyunsaturated fatty acids may impair blood glucose control in type 2 diabetic patients. Diabet Med 1992;9:126-33.
205. von Schacky C, Fischer S, Weber PC. Long-term effects of dietary marine omega-3 fatty acids upon plasma and cellular lipids, platelet function, and eicosanoid formation in humans. J Clin Invest 1985;76:1626-31.
206. Knapp HR, Reilly IA, Alessandrini P, FitzGerald GA. In vivo indexes of platelet and vascular function during fish-oil administration in patients with atherosclerosis. N Engl J Med 1986;314:937-42.
207. Terano T, Salmon JA, Higgs GA, Moncada S. Eicosapentaenoic acid as a modulator of inflammation. Effect on prostaglandin and leukotriene synthesis. Biochem Pharmacol 1986;35:779-85.
208. Weiner BH, Ockene IS, Levine PH et al. Inhibition of atherosclerosis by cod-liver oil in a hyperlipidaemic swine model. N Engl J Med 1986;315:841-6.
209. Kromhout D, Bosschieter EB, de Lezenne Coulander C. The inverse relation between fish consumption and 20-year mortality from coronary heart disease. N Engl J Med 1985;312: 1205-9.
210. Garg A, Bonanome A, Grundy SM, Zhang ZJ, Unger RH. Comparison of a high-carbohydrate diet with a high-mono-unsaturated-fat diet in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1988;319:829-34.
211. American Diabetes Association. Nutritional recommendations and principles for people with diabetes mellitus. Diabetes Care 1994;17:519-22.
212. Paisey R, Elkeles RS, Hambley J, Magill P. The effects of chlorpropamide and insulin on serum lipids, lipoproteins and fractional triglyceride removal. Diabetologia 1978;15:81-5.
213. Greenfield MS, Doberne L, Rosenthal M, Schulz B, Widstrom A, Reaven GM. Effect of sulfonylurea treatment on in vivo insulin secretion and action in patients with non-insulin-dependent diabetes mellitus. Diabetes 1982;31:307-12.
214. Howard BV, Howard WJ. Dyslipidaemia in non-insulin dependent diabetes mellitus. Endocrine Reviews 1995;15: 263-77.
215. Kolterman OG, Gray RS, Shapiro G, Scarlett JA, Griffin J, Olefsky JM. The acute and chronic effects of sulfonylurea therapy in type II diabetic subjects. Diabetes 1984;33:346-54.
216. Firth RG, Bell PM, Rizza RA. Effects of tolazamide and exogenous insulin on insulin action in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1986;314: 1280-6.
217. United Kingdom Prospective Diabetes Study Group. United Kingdom prospective diabetes study (UKPDS) 13: relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. B Med J 1995;310:83-8.
218. McGuinness OP, Green DR, Cherrington AD. Glyburide sensitizes perfused rat liver to insulin-induced suppression of glucose output. Diabetes 1987;36:472-6.
219. Beck Nielsen H, Pedersen O, Lindskov HO. Increased insulin sensitivity and cellular insulin binding in obese diabetics following treatment with glibenclamide. Acta Endocrinol Copenh 1979;90:451-62.
220. Beck Nielsen H, Hother Nielsen O, Pedersen O. Mechanism of action of sulphonylureas with special reference to the extrapancreatic effect: an overview. Diabet Med 1988;5: 613-20.
221. Reaven GM, Jeppesen J, Hollenbeck CB, Zhou MY, Chen YDI. Effect of metformin on post-prandial lipaemia in patients with uncontrolled non-insulin-dependent diabetes mellitus. Endocrine Society 76 th Annual Meeting, Anaheim, June 15-17. Rockville: The Endocrine Society Press, 1994: 394.
222. Lardinois CK, Greenfield MS, Schwartz HC, Vreman HJ, Reaven GM. Acarbose treatment of non-insulin-dependent diabetes mellitus. Arch Intern Med 1984;144:345-7.
223. Reaven GM, Lardinois CK, Greenfield MS, Schwartz HC, Vreman HJ. Effect of acarbose on carbohydrate and lipid metabolism in NIDDM patients poorly controlled by sulfonylureas. Diabetes Care 1990;13 Suppl 3:32-6.
224. Hoffmann J, Spengler M. Efficacy of 24-week monotherapy with acarbose, glibenclamide or placebo in NIDDM patients. Diabetes Care 1994;17:561-6.
225. Agardh CD, Nilsson Ehle P, Schersten B. Improvement of the plasma lipoprotein pattern after institution of insulin treatment in diabetes mellitus. Diabetes Care 1982;5:322-5.
226. Rabkin SW, Boyko E, Streja DA. Changes in high density lipoprotein cholesterol after initiation of insulin therapy in non-insulin dependent diabetes mellitus: relationship to changes in body weight. Am J Med Sci 1983;285:14-20.
227. Hollenbeck CB, Chen YD, Greenfield MS, Lardinois CK, Reaven GM. Reduced plasma high density lipoprotein-cholesterol concentrations need not increase when hyperglycaemia is controlled with insulin in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1986;62:605-8.
228. Taskinen MR, Kuusi T, Helve E, Nikkila EA, Yki Jarvinen H. Insulin therapy induces antiatherogenic changes of serum lipoproteins in noninsulin-dependent diabetes. Arteriosclerosis 1988;8:168-77.
229. Bagdade JD, Buchanan WE, Kuusi T, Taskinen MR. Persistent abnormalities in lipoprotein composition in noninsulin-dependent diabetes after intensive insulin therapy. Arteriosclerosis 1990;10:232-9.
230. Taskinen MR, Packard CJ, Shepherd J. Effect of insulin therapy on metabolic fate of apolipoprotein B-containing lipoproteins in NIDDM. Diabetes 1990;39:1017-27.
231. Janka HU, Ziegler AG, Standl E, Mehnert H. Daily insulin dose as a predictor of macrovascular disease in insulin treated non-insulin-dependent diabetics. Diab Metab 1987;13:359-64.
232. Stout RW, Bierman EL, Ross R. Effect of insulin on the proliferation of cultured primate arterial smooth muscle cells. Circ Res 1975;36:319-27.
233. Pfeifle B, Ditschuneit H. Effect of insulin on growth of cultured human arterial smooth muscle cells. Diabetologia 1981;20:155-8.
234. Mazzone T, Foster D, Chait A. In vivo stimulation of low-density lipoprotein degradation by insulin. Diabetes 1984;33: 333-8.
235. Oppenheimer MJ, Sundquist K, Bierman EL. Downregulation of high-density lipoprotein receptor in human fibroblasts by insulin and IGF-I. Diabetes 1989;38:117-22.
236. The Diabetes Control and Complications Trial Study Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86.
237. Bianchi R, Erkelens DW. Diabetes mellitus, lipids and insulin resistance. Diab Nutr Metab 1994;7:1-9.
238. Vinik AI, Colwell JA, and the Hyperlipidaemia in Diabetes Investigators. Effects of gemfibrozil on triglyceride levels in patients with NIDDM. Diabetes Care 1993;16:37-44.
239. Shen DC, Fuh MM, Shieh SM, Chen YD, Reaven GM. Effect of gemfibrozil treatment in sulfonylurea-treated patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1991;73:503-10.
240. Garg A, Grundy SM. Gemfibrozil alone and in combination with lovastatin for treatment of hypertriglyceridaemia in NIDDM [published erratum appeared in Diabetes 1990; 39(10):1313]. Diabetes 1989;38:364-72.
241. Vuorinen Markkola H, Yki Jarvinen H, Taskinen MR. Lowering of triglycerides by gemfibrozil affects neither the gluco-regulatory nor antilipolytic effect of insulin in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1993;36: 161-9.
242. Kesaniemi YA, Grundy SM. Influence of gemfibrozil and clofibrate on metabolism of cholesterol and plasma triglycerides in man. JAMA 1984;251:2241-6.
243. Syvänne M, Vuorinen Markkola H, Hilden H, Taskinen MR. Gemfibrozil reduces post-prandial lipaemia in non-insulin-dependent diabetes mellitus. Arterioscler Thromb 1993;13: 286-95.
244. Saku K, Gartside PS, Hynd BA, Kashyap ML. Mechanism of action of gemfibrozil on lipoprotein metabolism. J Clin Invest 1985;75:1702-12.
245. Wang CS, McConathy WJ, Kloer HU, Alaupovic P. Modulation of lipoprotein lipase activity by apolipoproteins. Effect of apolipoprotein C-III. J Clin Invest 1985;75:384-90.
246. Ginsberg HN, Le NA, Goldberg IJ et al. Apolipoprotein B metabolism in subjects with deficiency of apolipoprotein CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo. J Clin Invest 1986;78:1287-95.
247. Vega GL, Grundy SM. Gemfihrozil therapy in primary hypertriglyceridaemia associated with coronary heart disease. Effects on metabolism of low-density lipoproteins. JAMA 1985;253:2398-403.
248. Lahdenpera S, Tilly Kiesi M, Vuorinen Markkola H, Kuusi T, Taskinen MR. Effects of gemfibrozil on low-density lipoprotein particle size, density distribution, and composition in patients with type II diabetes. Diabetes Care 1993;16:584-92.
249. Frick MH, Elo O, Haapa K et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidaemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987;317:1237-45.
250. Koskinen P, Mänttäri M, Manninen V, Huttinen JK, Heinonen OP, Frick MH. Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes Care 1992;15:820-5.
251. The Expert Panel: Report of the National Cholesterol Education Program expert panel on detection, evaluation and treatment of high blood cholesterol in adults. Arch Intern Med 1988;148:36-69.
252. Garg A, Grundy SM. Nicotinic acid as therapy for dyslipidaemia in non-insulin-dependent diabetes mellitus. JAMA 1990;264:723-6.
253. Kahn SE, Beard JC, Schwartz MW et al. Increased beta-cell secretory capacity as mechanism for islet adaptation to nicotinic acid-induced insulin resistance. Diabetes 1989;38:562-8.
254. Garg A, Grundy SM. Management of dyslipidaemia in NIDDM. Diabetes Care 1990;13:153-69.
255. Vaag A, Skott P, Damsbo P, Gall MA, Richter EA, Beck Nielsen H. Effect of the antilipolytic nicolinic acid analogue acipimox on whole-body and skeletal muscle glucose metabolism in patients with non-insulin-dependent diabetes mellitus. J Clin Invest 1991;88:1282-90.
256. Fulcher GR, Walker M, Farrer M, Johnson AS, Alberti KG. Acipimox increases glucose disposal in normal man independent of changes in plasma nonesterilied fatty acid concentration and whole-body lipid oxidation rate. Metabolism 1993;42:308-14.
257. Saloranta C, Taskinen M-R, Widen E, Härkönen, Melander A, Groop L. Metabolic consequences of sustained suppression of free fatty acids by acipimox in patients with NIDDM. Diabetes 1993;42:1559-66.
258. Puhukainen I, Yki-Järvinen H. Inhibition of lipolysis decreases lipid oxidation and gluconeogenesis from lactate but not fasting hyperglycaemia or total hepatic glucose production in NIDDM. Diabetes 1993;42:1694-9.
259. Bandisode MS, Boshell BR. Hypocholesterolemic activity of colestipol in diabetes. Curr Ther Res 1974;18:276-84.
260. Crouse JR. Hypertriglyceridaemia: a contraindication to the use of bile acid binding resins. Am J Med 1987;83:243-8.
261. Garg A, Grundy SM. Cholestyramine therapy for dyslipidaemia in non-insulin-dependent diabetes mellitus. A short-term, double-blind, crossover trial. Ann Intern Med 1994;121:416-22.
262. The Lipid Research Clinics Coronary Primary Prevention Trial Results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984;251:365-74.
263. Garg A, Grundy SM. Lovastatin for lowering cholesterol levels in non-insulin-dependent diabetes mellitus. N Engl J Med 1988;318:81-6.
264. Uauy R, Vega GL, Grundy SM, Bilheimer DM. Lovastatin therapy in receptor-negative homozygous familial hypercholesterolemia: lack of effect on low-density lipoprotein concentrations or turnover. J Pediatr 1988;113:387-92.
265. Vega GL, East C, Grundy SM. Lovastatin therapy in familial dysbetalipoproteinaemia: effects on kinetics of apolipoprotein B. Atherosclerosis 1988;70:131-43.
266. Vega GL, Grundy SM. Influence of lovastatin therapy on metabolism of low density lipoproteins in mixed hyperlipidaemia. J Intern Med 1991;230:341-50.